Recipient of federal assistance · ROCKVILLE, MD

RISE THERAPEUTICS LLC

RISE THERAPEUTICS LLC received $4.1M in federal grants and other assistance in FY2026, on 10 actions, +41% vs FY2025. It has no federal contracts in the loaded years. Since FY2021: $30.7M. Its largest awarding agency was National Institutes of Health ($4.1M).

Assistance · FY2026
$4.1M
New awards
2
Actions
10
Since FY2021
$30.7M
UEI
N36JMJ1DKWH6
Location
ROCKVILLE, MD
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 4.2MFY2021
  2. 6.3MFY2022
  3. 7.5MFY2023
  4. 5.7MFY2024
  5. 2.9MFY2025
  6. 4.1MFY2026

By type

  1. Grants$4.1M100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research$1.9M45%
  2. 93.866 · Aging Research$967.7K24%
  3. 93.395 · Cancer Treatment Research$740.1K18%
  4. 93.121 · Oral Diseases and Disorders Research$549.8K13%
  5. 93.855 · Allergy and Infectious Diseases Research-$5,9280.0%

Awarding agencies

  1. National Institutes of Health$4.1M100%
    Department of Health and Human Services

Largest awards

  1. A NOVEL IMMUNOLOGICAL-DIRECTED BIOTHERAPY FOR TREATING RHEUMATOID ARTHRITIS - PROJECT SUMMARY OUR GOAL IS TO DEVELOP A NOVEL…$3.4M
    93.866 · Aging Research· National Institutes of Health· Project grant· Sep 4, 2023 – Jul 28, 2026· R44AG084484
  2. A NOVEL PROBIOTIC FOR THE TREATMENT OF SJOGREN'S SYNDROME - PROJECT SUMMARY OUR GOAL IS TO DEVELOP A NOVEL, IMMUNOLOGICALLY ENHANCED L…$2.9M
    93.121 · Oral Diseases and Disorders Research· National Institutes of Health· Project grant· May 12, 2021 – Sep 8, 2026· SB1DE030833
  3. A NOVEL MICROBIOME-BASED IMMUNE-MODULATOR THAT POTENTIATES CANCER CHECKPOINT THERAPY - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO…$2.4M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Mar 31, 2021 – Jun 1, 2026· R44CA261509
  4. A NOVEL IMMUNOLOGICAL-DIRECTED LIVE BIOTHERAPY PRODUCT FOR TREATING ULCERATIVE COLITIS - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO…$2.3M
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Jul 4, 2022 – Jun 18, 2026· R44DK133061
  5. A NOVEL SYNTHETICALLY ENGINEERED ORAL IMMUNOTHERAPY FOR TREATING ULCERATIVE COLITIS - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO…$2.2M
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Sep 16, 2024 – Jul 16, 2026· SB1DK141356
  6. A NOVEL IMMUNOLOGICAL-DIRECTED SYNTHETIC BIOLOGY-BASED DRUG FOR THE TREATMENT OF MULTIPLE SCLEROSIS - PROJECT SUMMARY OUR GOAL IS TO…$2.1M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Apr 24, 2023 – Apr 1, 2026· R44AI174844

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2021–FY2026.